Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 18/20 | 0.73 |
| ▸ | PDE4D | Q08499 | 14/20 | 0.61 |
| ▸ | PDE4A | P27815 | 12/20 | 0.47 |
| ▸ | PDE4C | Q08493 | 12/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1301229 | 0.91 | PDE4D (0.75) | PDE4BPDE4DPDE4APDE4C | |
| SCHEMBL4029909 | 0.85 | PDE4D (0.81) | PDE4BPDE4DPDE4APDE4C | |
| SCHEMBL1302066 | 0.85 | PDE4B (1.00) | PDE4BPDE4DPDE4APDE4C | |
| SCHEMBL12108289 | 0.81 | PDE4B (0.84) | PDE4BPDE4D | |
| SCHEMBL4029740 | 0.77 | PDE4D (0.69) | PDE4BPDE4DPDE4APDE4C | |
| SCHEMBL4866907 | 0.76 | PDE4D (0.68) | PDE4BPDE4DPDE4APDE4C | |
| Oglemilast SCHEMBL29369504 | 0.76 | PDE4D (1.00) | PDE4BPDE4DPDE4APDE4C | |
| Oglemilast SCHEMBL29413215 | 0.76 | PDE4D (1.00) | PDE4BPDE4DPDE4APDE4C | |
| Oglemilast SCHEMBL220245 | 0.76 | PDE4D (1.00) | PDE4BPDE4DPDE4APDE4C | |
| SCHEMBL12108272 | 0.75 | PDE4B (0.60) | PDE4BPDE4DPDE4APDE4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8580795-B2 | Heterocyclic compounds as phosphodiesterase inhibitors | ORCHID CHEMICALS & PHARMACEUTICALS LIMITED (IN) | 2013-11-12 | — | — | US | disclosed |
| US-20110269753-A1 | HETEROCYCLIC COMPOUNDS AS PHOSPHODIESTERASE INHIBITORS | ORCHID RESEARCH LABORATORIES LTD. (IN) | 2011-11-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110269753-A1 | HETEROCYCLIC COMPOUNDS AS PHOSPHODIESTERASE INHIBITORS | PDE4A, PDE4B, PDE4C | PDE4B 2/4885PDE4D 4/4885PDE4A 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.